[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lyme-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lyme-disease":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,41,62,91,109,121,153,187,213,236,265,304,336,743,796],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":4,"leadSponsor":37,"locationsCount":40},"100054269",false,"NCT00028080","Evaluation, Treatment, and Follow-up of Patients With Lyme Disease","* INCLUSION CRITERIA:\n* Clinical diagnosis of active Lyme disease at the time of the initial NIH evaluation based on the CDC case definition. Study physician will review history to confirm probable cases.\n* Subjects must maintain a private physician for non-protocol related medical complaints and for emergency medical treatment required for these or other of their disorders.\n\nEXCLUSION CRITERIA:\n\n* Post treatment Lyme disease syndrome.\n* Unacceptably poor compliance, which, in the opinion of the investigator, would interfere with one's ability to study or provide quality medical care for the patient.\n\nELIGIBILITY CRITERIA TO BE ASKED TO UNDERGO APHERESIS INCLUDE:\n\n* Age 18 years or above\n* Weight greater than 110 pounds\n* No known heart, lung, kidney disease, or bleeding disorders\n* Negative HIV, HCV and HBsAg serologies\n* Female subjects should not be pregnant or nursing\n* Adequate peripheral venous access\n\nPatients will have a CBC performed up to 2 weeks before the procedure. In order to be able to undergo the procedure, patient must fulfill all of the below:\n\n* Hemoglobin greater than 11 g\u002FdL for males and greater than 10 g\u002FdL for females\n* Platelets greater than 150 k\u002Fmm(3)\n* WBC greater than 3.5 x 10(3) uL\n* MCV above 80\n\nWomen who are able to conceive children must have a negative pregnancy test within 2 weeks before the procedure.","ALL","2 Years","99 Years",{"count":18,"type":19},500,"ESTIMATED","OBSERVATIONAL","This study is designed to establish a population of patients with Lyme disease for evaluation, treatment and follow-up to learn more about the infection.\n\nPatients with active Lyme disease may be eligible for this study.\n\nParticipants will have a medical history and physical examination and diagnostic evaluations as appropriate to their individual condition. Laboratory tests may include routing blood and urine tests, X-rays, or other imaging studies, body fluid or tissue cultures, skin biopsy and tests for allergic or immune responses. Treatment will include only medications approved by the Food and Drug Administration, given according to accepted dose schedules and ways of taking the medicines. All diagnostic tests and treatments will be according to standard medical practice for the disease. No experimental procedures will be offered under this protocol.\n\nPatients will be followed as needed for evaluation and treatment of their condition. In general, they will be asked to return at the end of therapy, then 3, 6 and 12 months later, and then every 6 to 12 months. More frequent visits may be required or less frequent visits may be allowed, depending on the individual s condition.\n\nParticipants may be asked to undergo the following additional procedures for research purposes:\n\n* Extra blood draws to study Lyme disease and other inflammatory conditions. Blood will be drawn from arm veins. The total amount drawn during any 6-week period will not exceed 450 cc (30 tablespoons) for adults and 7 cc (1\u002F2 tablespoon) per kilogram (2.2 pounds) of body weight for children under 18 years of age.\n* Leukapheresis to collect large numbers of white blood cells. Whole blood is collected through a needle in an arm vein, similar to donating blood. The blood circulates through a machine that separates it into its components, and the white cells are removed. The rest of the blood is returned to the body through the same needle. Only adults 18 years of age and older will be asked to undergo leukapheresis.",[23],"Lyme Disease",[25,23,26,27,28,29],"Borrelia Burgdorferi","Infection","Therapy","Natural History","Lyme","RECRUITING","2026-07-10",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2002-01-16",{"name":38,"class":39},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",1,{"id":42,"slug":43,"hasResults":10,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":14,"minAge":48,"maxAge":16,"enrollmentInfo":49,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":4,"leadSponsor":61,"locationsCount":40},"100054554","a-comprehensive-clinical-microbiological-and-immunological-assessment-of-patients-with-suspected-post-treatment-lyme-disease-syndrome-and-selected-control-populations-100054554","NCT00001539","A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations","* INCLUSION CRITERIA:\n\nSCREENING FOR SUSPECTED PTLDS\n\nAge \\>= 13 years old, suspect of suffering from Lyme disease\n\nPOST-TREATMENT LYME DISEASE SYNDROME (PTLDS)\n\nFor the purposes of this study, PTLDS is defined as (1) occurring in male or female patients aged 13 and above (2) who have been diagnosed with confirmed or probable Lyme disease per CDC definition (https:\u002F\u002Fwwwn.cdc.gov\u002Fnndss\u002Fconditions\u002Flyme-disease\u002Fcase-definition\u002F2017\u002F). Study physician will review history to confirm probable cases. (3) They have received recommended antibiotic therapy (4) and have persistent or relapsing symptoms and\u002For signs for at least six months after therapy \\[4, 5\\]. (5) They also should have no other documented explanation for their signs and symptoms.\n\nLYME ARTHRITIS CONTROLS\n\nFor the purposes of this study, Lyme arthritis is defined as occurring in an otherwise healthy male or female aged 18 and above who have intermittent episodes of arthritis involving one or few joints, without any other cause being documented, and have positive serum antibodies to B. burgdorferi confirmed by IgG Western blot according to the CDC criteria.\n\nRECOVERED CONTROLS\n\nFor the purposes of this study, a recovered control is defined as an otherwise healthy male or female aged 18 and above who has had confirmed or probable Lyme disease, fulfilling the CDC Lyme Disease National Surveillance Case Definition (appendix 5), and who had received accepted antibiotic treatment for Lyme disease \\[5\\] (at least 3 months since the end of antibiotic therapy before protocol evaluation) and who are currently asymptomatic.\n\nSEROPOSITIVE CONTROLS\n\nFor the purposes of this study, a seropositive control is defined as an otherwise healthy male or female aged 18 and above who has positive serum IgG antibody response to B. burgdorferi by Western blot according to the CDC criteria and are asymptomatic and who recall no episodes of disease compatible with Lyme infection and have not received antibiotic therapy for Lyme\n\ndisease.\n\nOSPA VACCINATED CONTROL\n\nFor the purposes of this study, an OspA vaccinated control is defined as an otherwise healthy male or female age 18 and above who has received at least two doses of the OspA vaccine for Lyme disease (Lymerix ). These controls may have a positive ELISA for B. burgdorferi but a negative (or unreadable) IgG western blot.\n\nMULTIPLE SCLEROSIS CONTROLS\n\nFor the purposes of this study, a multiple sclerosis control is defined as an otherwise healthy male or female aged 18 and above with relapsing-remitting or progressive multiple sclerosis as defined by the Clinical Trial Committee of the National Multiple Sclerosis Society and no evidence of prior exposure to B. burgdorferi as indicate by negative history for Lyme disease and negative western blot for B. burgdorferi in the serum by the CDC criteria. Patients should have a Kurtzke or Expanded Disability Status Scale (EDSS) between 1 and 5.\n\nHEALTHY VOLUNTEERS\n\nFor the purpose of this study, a healthy volunteer is defined as healthy male or female, age 18 and above, with no history compatible with Lyme disease and negative serological testing to B. burgdorferi by the CDC criteria.\n\nGENERAL EXCLUSION CRITERIA\n\n1. Age less than 18 (less than 13 for patients with PTLDS)\n2. Weight less than 70 Lb. (35 kg)\n3. Pregnancy or lactation\n4. Women with childbearing potential who are sexually active with a male partner and unwilling to use effective contraception during the evaluation and treatment phases of the protocol.\n5. Clinically significant laboratory abnormalities including positive test for syphilis (RPR), HBsAg, anti-HCV, anti-HIV.\n6. Chronic medication use will be evaluated in a case-by-case basis.\n7. Not able to understand all of the requirements of the study or unable to give informed consent and\u002For comply with all aspects of the evaluation.\n8. All study participants must agree to allow their samples to be used for future research.\n\nEXCLUSION CRITERIA FOR PTLDS PATIENTS AND LYME ARTHRITIS CONTROLS:\n\nIn addition to the general exclusion criteria, these individuals will be excluded for:\n\n1. Use of immunosuppressive drugs such as systemic (but not topical or inhalant) steroids and cytotoxic agents.\n2. History of any recognized autoimmune disease such as rheumatoid arthritis, vasculitis, systemic erythematous lupus, etc.\n3. Serious pre-existing or concurrent chronic medical or psychiatric illnesses other than Lyme disease.\n4. Past history of significant head trauma, alcohol or substance abuse in the past 5 years or other medical illness that might produce neurologic deficit (such as cerebrovascular disease).\n5. Use of systemic antibiotics in the previous month.\n6. Use of immunomodulators such as interferons.\n7. Chronic medication use will be evaluated in a case-by-case basis\n8. Patients will be excluded from this protocol if they are judged by the principal investigator as having a significant impairment in their capacity for judgment and reasoning that compromise their ability to make decisions in their best interest.\n\nEXCLUSION CRITERIA FOR RECOVERED, SEROPOSITIVE, OSPA VACCINATED AND HEALTHY VOLUNTEERS CONTROLS:\n\nIn addition to the above applicable exclusion criteria (general exclusion criteria and exclusion criteria for PTLDS patients and Lyme arthritis controls), these individuals will be excluded for:\n\n1\\. Pre-existing or concurrent serious chronic medical or psychiatric illness.\n\nEXCLUSION CRITERIA FOR MULTIPLE SCLEROSIS CONTROLS:\n\nIn addition to the above general exclusion criteria, these individuals will be excluded for:\n\n1. Pre-existing or concurrent serious psychiatric or chronic medical illness besides Multiple Sclerosis.\n2. Past history of significant head trauma, alcohol or substance abuse in the past 5 years or other medical illness, besides Multiple Sclerosis, that might produce neurologic deficit (such as cerebrovascular disease).\n3. Previously received total lymphoid irradiation (TLI) or cladribine.\n4. Has used immunoactive medications (excluding beta-interferon) in the three months preceding the study.\n5. In the three months prior to the study initiation, was given such investigational treatments as plasmapheresis, hyperbaric oxygen, gangliosides, Copolymer 1, etc.\n\nELIGIBILITY OF SPECIAL POPULATIONS\n\nChildren: Children 13 years and older are eligible to participate in the PTLDS cohort because the condition under study can affect children. This age was selected as appropriate for the children to provide assent to and comply with the study procedures. Children younger than 13 will be excluded from the PTLDS cohort, and no children will be enrolled in the other study cohorts.\n\nPregnant and lactating women: Pregnant and lactating women are excluded from study participation. An enrolled participant who becomes pregnant during the study will be withdrawn\n\nAdults who lack capacity to consent: Adults who lack decision-making capacity to provide informed consent are excluded at screening, and enrolled adult participants who permanently lose the ability to consent during study participation will be withdrawn\n\nNIH staff members: NIH staff may be enrolled if they meet eligibility criteria. Neither participation nor refusal to participate as a subject in the research will have an effect, either beneficial or adverse, on the participant s employment or position at NIH. Every effort will be made to protect participant information, but such information may be available in medical records and may be available to authorized users outside of the study team in both an identifiable and unidentifiable manner.",true,"13 Years",{"count":50,"type":19},700,"This study will determine whether patients who have been infected with the Lyme bacteria, Borrelia burgdorferi, and treated with antibiotics still have the bacteria alive inside them and whether it is causing their symptoms. The information from this study may serve as a basis for developing stringent diagnostic criteria for Lyme disease and the establishment of future treatment trials.\n\nIndividuals in the following categories may be eligible for this study: chronic Lyme disease; chronic Lyme arthritis; seropositive control (are infected with the bacteria that causes Lyme disease but do not have disease symptoms); recovered control (have been sick with Lyme disease but were treated successfully and are currently well); control with multiple sclerosis (patients with multiple sclerosis); and healthy volunteers. Patients in the chronic Lyme disease category must be age 13 and above; all others must be age18 and above. Candidates will be screened with blood and urine tests.\n\nParticipants will have a physical examination and the following tests:\n\nBlood tests Includes HLA-typing, a genetic test of immune system markers;\n\nLeukapheresis Collection of large numbers of white blood cells Whole blood is collected through a needle in an arm vein. The blood circulates through a machine that separates it into its components. The white cells are removed and the rest of the blood is returned to the body, either through the same needle used to draw the blood or through another needle in the other arm. (Alternatively, patients will 100 cc (about 7 tablespoons) of blood drawn.);\n\nLumbar puncture (spinal tap) Collection of cerebrospinal fluid (CSF, fluid that bathes the brain and spinal cord). A local anesthetic is administered and a needle is inserted in the space between the bones in the lower back where the cerebrospinal fluid circulates below the spinal cord. A small amount of fluid is collected through the needle;\n\nMagnetic resonance imaging (MRI) of the brain Imaging of the brain using a strong magnetic field and radio waves instead of X-rays. During the scan, the patient lies on a table in a narrow cylinder containing a magnetic field. He or she can speak with a staff member via an intercom at all times during the procedure;\n\nNeuropsychologic testing;\n\nSome participants may also have a hearing test and urine collection.\n\nParticipants whose test results are positive for Borrelia burgdorferi will be followed at NIH at intervals of 3 to 6 months until it is determined whether there is infection. Those who are infected will be offered treatment with the antibiotic ceftriaxone. Following treatment, patients will return to the NIH Clinical Center for follow-up visits 1 week after treatment and again at 3, 6 and 12 months. The lumbar puncture, hearing examination, blood and urine tests will be repeated at these visits to evaluate the response to treatment, and the leukapheresis will be repeated for research purposes. Patients whose MRI was abnormal during therapy will have a repeat MRI at the 3-month, 6-month and 1-year visits.\n\nAll participants with chronic Lyme disease, chronic Lyme arthritis, seropositive controls and recovered controls may be reevaluated at intervals of 6 to 12 months.\n\n...",[23],[25,54,55,28,23],"Lyme Borreliosis","Tick-Borne Disease","2026-06-27",{"date":58,"type":34},"2026-06-30",{"date":60,"type":34},"1996-06-13",{"name":38,"class":39},{"id":63,"slug":64,"hasResults":10,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":10,"sex":69,"minAge":70,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":40},"100546657","navigating-pregnancy-and-parenthood-with-lyme-disease-100546657","NCT06397794","Navigating Pregnancy and Parenthood With Lyme Disease","Mixed Methods Study on Navigating Pregnancy and Parenthood With Lyme Disease","Inclusion Criteria:\n\n* Over 18 years of age and reside in the United States or Canada\n* Diagnosed with acute Lyme disease, PTLDS, and\u002For Chronic Lyme by a health care provider while they were pregnant OR PTLDS\u002FCL prior to becoming pregnant with ongoing symptoms during pregnancy\n\nExclusion Criteria:\n\n* Under 18 years of age\n* Live outside of the United States or Canada\n* Never been diagnosed with Lyme disease by a medical provider\n* Never been pregnant\n* Never given birth to a liveborn infant\n* Previously participated in a qualitative study about their experience with Lyme disease\n* Do not want to agree to having their interviews audio recorded","FEMALE","18 Years",{"count":72,"type":19},30,"This is a mixed methods study exploring the experiences of pregnancy and parenting among participants with Lyme disease. Eligible participants will have been diagnosed with Lyme disease (LD), post-treatment Lyme disease syndrome (PTLDS), and\u002For chronic Lyme (CL) either during or before a prior pregnancy. Participants will complete quantitative surveys on topics such as their medical history, their child(ren)'s development, and demographic information. They will then participate in a qualitative interview where they will be asked about their experiences with pregnancy and with parenting their child(ren) in the context of their condition.",[23,75,76,77,78,79,80],"Post Treatment Lyme Disease","Chronic Lyme Disease","Tick-Borne Infections","Tick-Borne Diseases","Pregnancy Complications","Parenting","2026-06-15",{"date":83,"type":34},"2026-06-17",{"date":85,"type":34},"2024-03-20",{"date":87,"type":19},"2026-12",{"name":89,"class":90},"Children's National Research Institute","OTHER",{"id":92,"slug":93,"hasResults":10,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":10,"sex":14,"minAge":70,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":108,"locationsCount":40},"100518163","pregnancy-and-early-neurodevelopmental-outcomes-following-in-utero-lyme-disease-exposure-100518163","NCT06026969","Pregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure","Inclusion Criteria:\n\n* English speaker\n* Currently reside in the United States or Canada\n* Meet CDC criteria for: (1) clinical and\u002For laboratory diagnosis of Lyme disease during any stage of current pregnancy, OR (2) clinical diagnosis of PTLDS\u002FChronic Lyme within 3 years of current pregnancy\n* Able to be contacted for follow-up\n\nExclusion Criteria:\n\n* Intellectually unable to comprehend study procedures\n* Health issues or metallic implant that precludes undergoing MRI\n* Incapable of completing study requirements (note: inability to travel to Children's National for in-person follow-up \\[for example, due to bedrest, travel restrictions, or financial inability to travel\\] is NOT an exclusion criterion; any interested and eligible participants requiring \"remote only\" participation will be permitted to join the study and complete all requirements besides in-person follow-up)",{"count":98,"type":19},40,"The purpose of this pilot study is to assess the feasibility of longitudinal neurodevelopmental evaluation of fetuses and infants exposed to Lyme disease in utero. Participants with Lyme disease or Post-Treatment Lyme Disease Syndrome (PTLDS) will be recruited during pregnancy. Pregnancies will be monitored and infant development will be assessed from birth until age 18 months.",[23,101,76,77,79,102],"Post-Treatment Lyme Disease","Child Development",{"date":104,"type":34},"2026-06-16",{"date":106,"type":34},"2023-07-01",{"date":87,"type":19},{"name":89,"class":90},{"id":110,"slug":111,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":113,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":114,"keywords":115,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":4,"leadSponsor":120,"locationsCount":40},"100060192","evaluation-treatment-and-follow-up-of-patients-with-lyme-disease-100060192","* INCLUSION CRITERIA:\n* Clinical diagnosis of active Lyme disease at the time of the initial NIH evaluation based on the CDC case definition. Study physician will review history to confirm probable cases.\n* Subjects must maintain a private physician for non-protocol related medical complaints and for emergency medical treatment required for these or other of their disorders.\n\nEXCLUSION CRITERIA:\n\n* Post treatment Lyme disease syndrome.\n* Unacceptably poor compliance, which, in the opinion of the investigator, would interfere with one's ability to study or provide quality medical care for the patient.\n\nELIGIBILITY CRITERIA TO UNDERGO APHERESIS:\n\n* Age 18 years or above.\n* Weight greater than 110 pounds.\n* No known heart, lung, kidney disease, or bleeding disorders.\n* Negative HIV, HCV and HBsAg serologies.\n* Female subjects should not be pregnant or nursing.\n* Patients will have a CBC performed up to 2 weeks before the procedure. In order to be able to undergo the procedure, patient must fulfill all of the below:\n\n  * Hemoglobin greater than 11 g\u002FdL for males and greater than 10 g\u002FdL for females.\n  * Platelets greater than 150 k\u002Fmm(3).\n  * WBC greater than 3.5 x 10(3) uL.\n  * MCV above 80.\n\nWomen who are able to conceive children must have a negative pregnancy test within 2 weeks before the procedure.",{"count":18,"type":19},[23],[25,23,26,27,28,29],"2026-06-04",{"date":118,"type":34},"2026-06-05",{"date":36,"type":34},{"name":38,"class":39},{"id":122,"slug":123,"hasResults":10,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":47,"sex":14,"minAge":70,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":131,"phases":132,"briefSummary":134,"conditions":135,"keywords":136,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":152},"100636100","phase-2-a-study-to-evaluate-the-safety-reactogenicity-and-immunogenicity-of-mrna-1982-to-prevent-lyme-disease-in-healthy-participants-18-to-70-years-of-age-100636100","NCT07561294","A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)","A Phase 2, Randomized, Observer-blind, Dose-finding, Placebo-controlled Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982, an mRNA Vaccine to Prevent Lyme Disease in Healthy Adult Participants (18 to 70 Years of Age)","Key Inclusion Criteria:\n\n* In good general health in the opinion of the investigator as determined by medical evaluation including medical history and physical examination at screening.\n* Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\nKey Exclusion Criteria:\n\n* History of anaphylaxis or severe hypersensitivity reaction requiring medical intervention after receipt of any mRNA vaccine or therapeutic or any components of an mRNA vaccine or therapeutic.\n* Have chronic illness related to Lyme disease or an active symptomatic Lyme disease infection as suspected or diagnosed by a physician.\n* Received treatment for Lyme disease within the prior 3 months.\n* Previously vaccinated against Lyme disease or participated in the past in any vaccine study for Lyme disease.\n* Had a tick bite within 4 weeks prior to Day 1.\n\nNote: Additional inclusion\u002Fexclusion criteria may apply, per protocol.","70 Years",{"count":130,"type":19},350,"INTERVENTIONAL",[133],"PHASE2","This clinical study will evaluate the safety, reactogenicity, and immunogenicity of monovalent mRNA-1982, a messenger ribonucleic acid (mRNA) vaccine to prevent Lyme disease in healthy adults aged 18 to 70 years old.",[23],[137,138,139,140,141],"Moderna","mRNA-1982","Messenger RNA","Safety","Vaccines","2026-05-27",{"date":144,"type":34},"2026-05-28",{"date":146,"type":34},"2026-04-29",{"date":148,"type":19},"2028-11-09",{"name":150,"class":151},"ModernaTX, Inc.","INDUSTRY",8,{"id":154,"slug":155,"hasResults":10,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":47,"sex":14,"minAge":70,"maxAge":128,"enrollmentInfo":160,"targetDuration":4,"studyType":131,"phases":161,"briefSummary":162,"conditions":163,"keywords":164,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":186},"100636161","phase-2-a-study-to-evaluate-safety-and-efficacy-of-tp-05-in-healthy-participants-with-tick-exposure-100636161","NCT07562087","A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure","A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TP-05 in Healthy Participants at High Risk of Tick Exposure","Inclusion Criteria:\n\n* Overtly healthy adult participants aged 18 to 70 years\n* Able to provide written informed consent\n* Willing and able to comply with study procedures\n* At high risk of exposure to ticks\n* Contraceptive use by men and women consistent with local regulations\n\nExclusion Criteria:\n\n* Prior exposure to TP05 or any isooxazoline in the last 12 months\n* Known hypersensitivity to TP05 or related compounds\n* Clinically significant medical conditions that may interfere with study participation\n* Use of investigational products within 30 days prior to screening.\n* Received previous vaccination against Lyme borreliosis, including investigational vaccines intended to prevent Lyme borreliosis\n* Receiving long-term antibiotic therapy\n* Received active or passive immunization within 4 weeks prior to Day\n* Pregnant or breastfeeding individuals",{"count":50,"type":19},[133],"This study is designed to evaluate the safety, tolerability, and pharmacokinetics of TP05 administered orally to healthy adult participants.",[23],[23,54,29,165,166,167,168,169,170,171,172,173,174,175,78,176],"Borrelia","Preventative Therapeutic","Prophylaxis","Healthy Volunteers","Randomized Controlled Trial","Gram-Negative Bacterial Infections","Bacterial Infections","Bacterial Infections and Mycoses","Infections","Borrelia Infections","Spirochaetales Infections","Vector Borne Diseases","2026-05-18",{"date":179,"type":34},"2026-05-20",{"date":181,"type":34},"2026-03-09",{"date":183,"type":19},"2027-12",{"name":185,"class":151},"Tarsus Pharmaceuticals, Inc.",19,{"id":188,"slug":189,"hasResults":10,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":47,"sex":14,"minAge":70,"maxAge":16,"enrollmentInfo":194,"targetDuration":4,"studyType":131,"phases":196,"briefSummary":198,"conditions":199,"keywords":202,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":40},"100442078","phase-1-human-immune-response-to-ixodes-scapularis-tick-bites-100442078","NCT05036707","Human Immune Response to Ixodes Scapularis Tick Bites","Investigating the Human Immune Response to Ixodes Scapularis Tick Bites","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Stated willingness to comply with all study procedures and availability for the duration of the study.\n2. Age 18 years or older.\n3. In good general health as evidenced by medical history.\n4. No history of TBD.\n5. No known tick bite.\n6. Serum IgE level within Clinical Center Department of Laboratory Medicine normal range.\n\n   https:\u002F\u002Fccinternal2.cc.nih.gov\u002FLTGRA\u002FUL\u002Fpublic\\_labtest\\_detail.aspx?next\\_flg=Y\\&test\\_id=4731\\&id\\_order=53\n7. Serum tryptase level within Clinical Center Department of Laboratory Medicine normal range.\n\n   https:\u002F\u002Fccinternal2.cc.nih.gov\u002FLTGRA\u002FUL\u002Fpublic\\_labtest\\_detail.aspx?next\\_flg=Y\\&test\\_id=1157\\&id\\_order=1\n8. For participants of child-bearing potential: use of effective contraception for at least 1 month prior to tick placement, and agreement to use such a method during study participation and for an additional 3 months after the removal of the last ticks. Types of contraception include abstinence, surgical methods (sterilization, implants, intrauterine device, partner with vasectomy), hormonal methods (birth control pill, patch, ring, injection), or barrier methods (diaphragm plus spermicide, male condom plus spermicide)\n9. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner.\n10. Agree to not participate in other clinical studies requiring investigational interventions for the duration of the study.\n11. Minimum hemoglobin of 13.0 g\u002FdL for males and 12 g\u002FdL for females\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. History of forming large thick scars (keloids) after skin injuries.\n2. History of excessive bleeding after cuts or procedures.\n3. History of taking anticoagulants in the past 28 days.\n4. History of allergic reaction to lidocaine.\n5. History of allergic reaction to tape, adhesive bandages, or dressings.\n6. Inability to maintain the dressing for any reason.\n7. Pregnancy or lactation.\n8. Treatment with another investigational drug or other intervention within the past 30 days.\n9. Oral or intravenous (IV) steroids in the 2 weeks prior to each tick placement procedure (topical, nasal, inhaled, intra-articular, and replacement doses of steroids are not exclusions).\n10. History of reactions to mammalian meat, IgE- mediated food allergies, urticaria or anaphylaxis. Mild pollen-food allergy syndrome is not an exclusion.\n11. History of systemic allergic reaction to venom (bee, wasps and other Hymenoptera stings).\n12. History of clinically significant drug allergies.\n13. History of moderate to severe atopy asthma, atopic dermatitis, allergic rhinitis.\n14. Active severe skin disease, uncontrolled diabetes, cancer other than non-melanoma skin cancers, autoimmune disease requiring immunosuppressive therapy, or history of human immunodeficiency virus (HIV), chronic viral hepatitis, or syphilis.\n15. Refusal to allow storage of samples and data for future usage..\n16. Any other condition that, in the opinion of the investigator, would make the patient unsuitable for enrollment or could interfere with the patient participating in and completing the study.\n\nExclusion of Select Populations:\n\nChildren:\n\nChildren are excluded from this protocol as there is no direct benefit to the participants, the risk from the skin biopsies is small but above minimal, the procedure is invasive and can be stressful for children, and there is concern over their ability to maintain the LeFlap dressing.\n\nPregnant and breastfeeding women:\n\nPregnant and breastfeeding women are excluded from trial participation as there is no direct benefit to the participants.\n\nAdults who lack capacity to consent:\n\nAdults lacking decision-making capacity to provide informed consent are excluded at screening as there is no direct benefit to the participants.\n\nEnrolled participants who permanently lose the ability to consent during participation will be monitored for safety but will have no additional research procedures performed.",{"count":195,"type":19},60,[197,133],"PHASE1","Background:\n\nEach year, the number of cases of tick-borne diseases increases. The deer tick (Ixodes scapularis) is the vector of at least 7 pathogens that cause human diseases, including Lyme disease. Researchers want to learn more to help them develop vaccines against ticks in the future.\n\nObjective:\n\nTo learn how people s bodies, particularly the skin, respond to tick bites.\n\nEligibility:\n\nHealthy adults aged 18 years and older who have no known history of a tick-borne disease or tick bite exposure.\n\nDesign:\n\nParticipants will be screened with a medical history, physical exam, and blood tests.\n\nParticipants will have 2 skin punch biopsies of healthy skin. For this, a sharp instrument will be used to remove a round plug of skin about the size of a pencil eraser. Participants will then have 10 clean laboratory-bred ticks placed at 2 different sites on their skin (20 ticks total). The ticks will be removed from the first site 1 day after placement and from the second site 2-4 days after placement. Participants will complete symptom diary cards. They will answer questions about itching at the tick feeding sites. They will give blood samples. Photos will be taken of the tick feeding sites. Skin punch biopsies will be collected at the sites of the tick bites.\n\nParticipants will repeat the tick feeding procedures 2 times, each 2-8 weeks apart. For the 2nd and 3rd procedures, 10 clean laboratory-bred ticks will be placed at 1 site. The ticks will be removed 2-3 days after tick placement. They will have telephone follow-up visits after each procedure.\n\nAfter the final tick removal, participants will have follow-up visits in 4-6 weeks and again in 3 months. They will give blood samples and discuss how they are feeling.\n\nParticipation will last about 5-7 months.",[200,201,23],"Tick-borne Diseases","Tick Resistance",[203,204,141,23],"Tick Immunity","Tick-borne diseases","2026-05-05",{"date":207,"type":34},"2026-05-06",{"date":209,"type":34},"2022-02-28",{"date":211,"type":19},"2028-06-30",{"name":38,"class":39},{"id":214,"slug":215,"hasResults":10,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":47,"sex":14,"minAge":220,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":131,"phases":223,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":235},"100631425","phase-3-a-study-to-learn-about-the-safety-tolerability-and-immunogenicity-of-a-fifth-dose-of-6-valent-ospa-based-lyme-disease-vaccine-100631425","NCT07500506","A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine","A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A FIFTH DOSE OF 6-VALENT OSPA-BASED LYME DISEASE VACCINE, VLA15, IN HEALTHY PARTICIPANTS ≥7 YEARS OF AGE","Inclusion Criteria:\n\n* Participants who are healthy as determined by medical history and clinical judgment.\n* Participants willing and able to comply with all scheduled visits, IP receipt, and other procedures throughout the study.\n* Able to provide Informed Consent.\n* Participants must have received 4 doses of VLA15 in the C4601003 study, and have a V7 blood sample available.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding participants.\n* Allergies or contraindications to vaccines or their components.\n* Health issues including: blood clotting deficiencies, immunodeficiencies, bone marrow disorder, or uncontrolled psychiatric conditions.\n* Receipt of therapies to treat malignancies, blood\u002Fplasma products and immunoglobulins, systemic corticosteroids and immunosuppressants, or anticoagulant therapy in recent medical history.\n* Recent or concurrent participation in a separate interventional study.\n* Staff or direct family of the study site staff and Sponsor.","7 Years",{"count":222,"type":19},1712,[224],"PHASE3","The purpose of this study is to learn about the safety effects of the Lyme disease vaccine (called VLA15), and its ability to protect people from Lyme disease after a 5th dose of the vaccine.\n\nThis study is seeking participants who:\n\n* are generally healthy and 7 years of age and older,\n* have already been vaccinated with 4 doses of VLA15 (from the VALOR study), and have blood sample taken post dose 4.\n* are not currently taking, or haven't recently taken, medicines like chemotherapy, blood products, or blood thinners.\n* are not pregnant or breastfeeding and do not plan to become pregnant while receiving the study vaccine.\n\nAll participants in this study will receive a total of 1 dose through a shot in the upper arm, either VLA15 or saline shot (saltwater).\n\nThe study will compare the experiences of people receiving the study vaccine or saltwater shot.\n\nParticipants will take part in this study for about 12 months. During this time, they will have 4 planned clinic visits. The clinic visits may include having a health check, giving a small amount of blood and getting the study vaccine or saltwater as a shot at the first visit.",[23],"2026-05-04",{"date":207,"type":34},{"date":230,"type":34},"2026-04-08",{"date":232,"type":19},"2026-12-04",{"name":234,"class":151},"Pfizer",22,{"id":237,"slug":238,"hasResults":10,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":47,"sex":14,"minAge":244,"maxAge":245,"enrollmentInfo":246,"targetDuration":248,"studyType":20,"phases":4,"briefSummary":249,"conditions":250,"keywords":251,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":40},"100519581","borrelia-b-cell-diagnostics-100519581","NCT06045416","Borrelia B-cell Diagnostics","Extensive Investigation of Immune Responses Against Borrelia Burgdorferi to Improve Diagnosis of Lyme Disease in Children: an Observational Study (BRILLIANT Study)","BRILLIANT","Inclusion Criteria:\n\n* Patients presenting at the ED with differential diagnosis of LD according to the treating physician\n\nExclusion Criteria:\n\n* Patients will be excluded in cases of primary or secondary immunodeficiency","1 Month","17 Years",{"count":247,"type":19},502,"6 Months","The investigators propose a single center, prospective observational study in children with Lyme disease (LD), the Borrelia B-cell diagnostics (BRILLIANT) study, to assess the immune response against Borrelia burgdorferi (Bb) with the following main objectives:\n\n1. Development of Bb-specific ASC ELISpot as a new test method for diagnosis of early LD.\n\n   There is an urgent unmet clinical need for a better diagnostic tool for early LD, as the current standard two-tier testing has low sensitivity in recently infected patients and may show false positive results in recovered patients due to long-term persistence of antibodies against Bb. The measurement of Bb-specific ASC with the ELISpot assay my has the potential to overcome these issues and to improve diagnosis in early LD.\n2. Extensive analysis of the immune response in LD. The immune response in LD is not well understood. Large-scale studies assessing the detailed immune cell subsets\u002Fphenotypes present in blood, CSF, or synovial fluid of LD patients with respective manifestations are lacking.\n3. Isolation and characterization of causative Bb species. Existing literature suggests that Bb genospecies and\u002For genotypes may determine virulence and manifestations, but large-scale studies assessing Bb genospecies\u002Fgenotypes in different manifestation of LD are lacking.\n4. Collection of clinical data about symptoms, severity, routine laboratory and diagnostic test results, treatment, and outcome of LD.\n5. Biobanking samples for analysis in the future.\n\nProject population\n\nInclusion criteria: Children, 0-17 years of age, at University Children's Hospital Zurich:\n\n* LD differential diagnosis cohort: Patients presenting at the ED with differential diagnosis of LD according to the treating physician.\n* Control cohort: Previously healthy patients (HC) with routine blood investigations presenting at the ED or PID outpatient department\n\nExclusion criteria: Primary or secondary immunodeficiency.",[23,174],[252,253,254,255],"Borrelia burgdorferi","Lyme disease","Borrelia specific ASCs","Borrelia strains","2026-04-27",{"date":258,"type":34},"2026-04-28",{"date":260,"type":34},"2024-04-02",{"date":262,"type":19},"2028-11-01",{"name":264,"class":90},"University Children's Hospital, Zurich",{"id":266,"slug":267,"hasResults":10,"nctId":268,"briefTitle":269,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":47,"sex":14,"minAge":70,"maxAge":16,"enrollmentInfo":271,"targetDuration":273,"studyType":20,"phases":4,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":40},"100393366","rheumatology-patient-registry-and-biorepository-100393366","NCT04402086","Rheumatology Patient Registry and Biorepository","Inclusion Criteria for Rheumatology Patients:\n\n* Patients ≥18 years old with a diagnosis of a rheumatic autoimmune disease including, but not limited to: adult onset Still's disease, ankylosing spondylitis, antiphospholipid syndrome, Behcet's disease, dermatomyositis, giant cell arteritis, mixed connective tissue disease, polymyalgia rheumatica, polymyositis, psoriatic arthritis, reactive arthritis, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus, undifferentiated connective tissue disease and vasculitis.\n* Receiving clinical care at Yale Rheumatology clinics\n\nExclusion Criteria for Rheumatology Patients:\n\n* Unable to provide informed consent\n* No patients will be excluded based on gender or ethnicity or pregnancy status.\n* Women who are currently pregnant will need to wait to donate a skin biopsy until after they deliver.\n* Patients allergic to lidocaine or epinephrine or have a history of impaired wound healing will not be able to donate a skin biopsy.\n\nInclusion Criteria for Healthy Volunteers:\n\n* Age ≥ 18 years old\n* No chronic skin conditions\n* No diagnosis of a rheumatic autoimmune disease (e.g., lupus, rheumatoid arthritis)\n* Normal BMI\n\nExclusion Criteria for Healthy Volunteers:\n\n* Unable to provide informed consent.\n* Currently pregnant or nursing unless the study goal is to study pregnant or nursing woman.\n* Allergies to lidocaine or epinephrine (skin biopsies).\n* A history of impaired wound healing (skin biopsies).",{"count":272,"type":19},5000,"10 Years","To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.",[276,277,278,279,280,281,282,283,284,285,286,23,287,288,289,290,291,292,293,294],"Rheumatic Diseases","Adult Onset Still Disease","Ankylosing Spondylitis","Psoriatic Arthritis","Reactive Arthritis","Antiphospholipid Syndrome","Systemic Lupus Erythematosus","Behcet Disease","Dermatomyositis","Polymyositis","Giant Cell Arteritis","Mixed Connective Tissue Disease","Polymyalgia Rheumatica","Rheumatoid Arthritis","Sarcoidosis","Systemic Sclerosis","Scleroderma","Sjogren's Syndrome","Undifferentiated Connective Tissue Diseases","2026-02-11",{"date":297,"type":34},"2026-02-13",{"date":299,"type":34},"2020-08-04",{"date":301,"type":19},"2030-06-01",{"name":303,"class":90},"Yale University",{"id":305,"slug":306,"hasResults":10,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":10,"sex":14,"minAge":312,"maxAge":313,"enrollmentInfo":314,"targetDuration":4,"studyType":131,"phases":316,"briefSummary":318,"conditions":319,"keywords":323,"overallStatus":326,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":40},"100557759","safety-and-effectiveness-of-the-blinker-system-in-participants-with-facial-nerve-palsy-100557759","NCT06542289","Safety and Effectiveness of the BlinkER System in Participants With Facial Nerve Palsy","Single-Arm, Multicenter Study to Evaluate the Safety and Effectiveness of the BlinkER System in Participants With Facial Nerve Palsy","Paralysis","Inclusion Criteria:\n\n22 years of age or older\n\n* Unilateral facial palsy due to any of the following: Bell's palsy, Ramsay Hunt syndrome, malignant or benign tumor resection, Lyme disease, cerebrovascular accident (hemorrhagic or ischemic), or trauma\n* A deficit in eye closure during blinking, defined as a mean blink score ≤2.0 in the study eye on the scale by Mäkelä, et al, as graded by the investigator.\n* Willing and able to comply with the study procedures and follow-up\n* Willing and able to provide informed consent\n* English, Spanish, or Hebrew, Arabic -speaking\n* In a trial with the BlinkER System, the device produces blinks sufficient to cover the pupil in the study eye, defined as a mean grade ≥ 3.0 on the Mäkelä scale, as graded by the investigator.\n* Participant successfully completes BlinkER System training and certification\n\nExclusion Criteria:\n\n* Bilateral facial paralysis (for example Parkinson's Disease)\n* History of prior intervention that is providing closure of the eyelids (e.g., facial reanimation, complete tarsorrhaphy surgery, etc.)\n* Has an implanted eyelid weight in the study eyelid.\n* History of diabetic neuropathy, unstable cardiovascular disease, neurologic disease causing severe cognitive or motor impairment, severe immunological deficiency, or malignant diseases that are not in remission\n* Signs of corneal infection, severe ocular surface inflammation, or significant periorbital skin inflammation\u002Finfection\n* Suspected or diagnosed epilepsy.\n* Cancerous lesions in the area where the BlinkER system electrodes will be applied.\n* Cardiac demand pacemaker, implanted defibrillator or other implanted electronic device\n* Cornea or iris abnormalities that preclude visualization of the pupil\n* Cranial nerve V palsy or neurotrophic keratitis\n* Synkinesis that results in eyelid closure\n* Known allergy to any of the patient-contacting materials of the BlinkeER electrode (i.e. polyethylene (PET) film tape or hydrogel)\n* Participants who are pregnant or nursing.\n* Participation in another ophthalmic clinical trial within one year prior to enrollment. Participant must also be willing to refrain from another ophthalmic study for the duration of the study.\n* Co-existing condition, either ocular or non-ocular that, in the judgement of the investigator could affect the safety or effectiveness of treatment or the compliance of the participant to the protocol.","22 Years","120 Years",{"count":315,"type":19},80,[317],"NA","Prospective, single-arm, multicenter, single-masked, pivotal study to Evaluate the Safety and Effectiveness of the Blinker system in Participants with Facial Nerve Palsy.",[320,321,23,322],"Bell's Palsy","Ramsay Hunt Syndrome","Facial Palsy",[324,325],"BlinkER System","BlinkER","NOT_YET_RECRUITING","2025-06-08",{"date":329,"type":34},"2025-06-10",{"date":331,"type":19},"2025-10-01",{"date":333,"type":19},"2026-11-30",{"name":335,"class":151},"Neurotrigger Ltd",{"id":337,"slug":338,"hasResults":10,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":10,"sex":14,"minAge":4,"maxAge":4,"enrollmentInfo":344,"targetDuration":346,"studyType":20,"phases":4,"briefSummary":347,"conditions":348,"keywords":690,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":733,"lastUpdatePostDateStruct":734,"startDateStruct":736,"completionDateStruct":738,"leadSponsor":740,"locationsCount":742},"100193378","rare-disease-patient-registry--natural-history-study---coordination-of-rare-diseases-at-sanford-100193378","NCT01793168","Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford","Coordination of Rare Diseases at Sanford","CoRDS","Inclusion Criteria:\n\n* Diagnosis of a rare disease, a disease of unknown prevalence, undiagnosed or an unaffected carrier of a rare\u002Funcommon disease\n\nExclusion Criteria:\n\n* Diagnosis of a disease which is not rare",{"count":345,"type":19},20000,"100 Years","CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, individuals and researchers to help in the advancement of research in over 7,000 rare diseases. The registry is free for patients to enroll and researchers to access. Visit sanfordresearch.org\u002FCoRDS to enroll.",[349,350,351,352,353,354,355,356,357,358,359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,23,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,401,402,403,404,405,406,407,408,409,410,411,412,413,414,415,416,417,418,419,420,421,422,423,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496,497,498,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,524,525,526,527,528,529,530,531,532,533,534,535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592,593,594,595,596,597,598,599,600,601,602,603,604,605,606,607,608,609,610,611,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,629,630,631,632,633,634,635,636,292,637,638,639,640,641,642,643,644,645,646,647,648,649,650,651,652,653,654,655,656,657,658,659,660,661,662,663,664,665,666,667,668,669,670,671,672,673,674,675,676,677,678,679,680,681,682,683,684,685,686,687,688,689],"Rare Disorders","Undiagnosed Disorders","Disorders of Unknown Prevalence","Cornelia De Lange Syndrome","Prenatal Benign Hypophosphatasia","Perinatal Lethal Hypophosphatasia","Odontohypophosphatasia","Adult Hypophosphatasia","Childhood-onset Hypophosphatasia","Infantile Hypophosphatasia","Hypophosphatasia","Kabuki Syndrome","Bohring-Opitz Syndrome","Narcolepsy Without Cataplexy","Narcolepsy-cataplexy","Hypersomnolence Disorder","Idiopathic Hypersomnia Without Long Sleep Time","Idiopathic Hypersomnia With Long Sleep Time","Idiopathic Hypersomnia","Kleine-Levin Syndrome","Kawasaki Disease","Leiomyosarcoma","Leiomyosarcoma of the Corpus Uteri","Leiomyosarcoma of the Cervix Uteri","Leiomyosarcoma of Small Intestine","Acquired Myasthenia Gravis","Addison Disease","Hyperacusis (Hyperacousis)","Juvenile Myasthenia Gravis","Transient Neonatal Myasthenia Gravis","Williams Syndrome","Myasthenia Gravis","Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome)","Isolated Klippel-Feil Syndrome","Frasier Syndrome","Denys-Drash Syndrome","Beckwith-Wiedemann Syndrome","Emanuel Syndrome","Isolated Aniridia","Axenfeld-Rieger Syndrome","Aniridia-intellectual Disability Syndrome","Aniridia - Renal Agenesis - Psychomotor Retardation","Aniridia - Ptosis - Intellectual Disability - Familial Obesity","Aniridia - Cerebellar Ataxia - Intellectual Disability","Aniridia - Absent Patella","Aniridia","Peters Anomaly - Cataract","Peters Anomaly","Potocki-Shaffer Syndrome","Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11","Silver-Russell Syndrome Due to Imprinting Defect of 11p15","Silver-Russell Syndrome Due to 11p15 Microduplication","Syndromic Aniridia","WAGR Syndrome","Wolf-Hirschhorn Syndrome","4p16.3 Microduplication Syndrome","4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome","Autosomal Recessive Stickler Syndrome","Stickler Syndrome Type 2","Stickler Syndrome Type 1","Stickler Syndrome","Mucolipidosis Type 4","X-linked Spinocerebellar Ataxia Type 4","X-linked Spinocerebellar Ataxia Type 3","X-linked Intellectual Disability - Ataxia - Apraxia","X-linked Progressive Cerebellar Ataxia","X-linked Non Progressive Cerebellar Ataxia","X-linked Cerebellar Ataxia","Vitamin B12 Deficiency Ataxia","Toxic Exposure Ataxia","Unclassified Autosomal Dominant Spinocerebellar Ataxia","Thyroid Antibody Ataxia","Sporadic Adult-onset Ataxia of Unknown Etiology","Spinocerebellar Ataxia With Oculomotor Anomaly","Spinocerebellar Ataxia With Epilepsy","Spinocerebellar Ataxia With Axonal Neuropathy Type 2","Spinocerebellar Ataxia Type 8","Spinocerebellar Ataxia Type 7","Spinocerebellar Ataxia Type 6","Spinocerebellar Ataxia Type 5","Spinocerebellar Ataxia Type 4","Spinocerebellar Ataxia Type 37","Spinocerebellar Ataxia Type 36","Spinocerebellar Ataxia Type 35","Spinocerebellar Ataxia Type 34","Spinocerebellar Ataxia Type 32","Spinocerebellar Ataxia Type 31","Spinocerebellar Ataxia Type 30","Spinocerebellar Ataxia Type 3","Spinocerebellar Ataxia Type 29","Spinocerebellar Ataxia Type 28","Spinocerebellar Ataxia Type 27","Spinocerebellar Ataxia Type 26","Spinocerebellar Ataxia Type 25","Spinocerebellar Ataxia Type 23","Spinocerebellar Ataxia Type 22","Spinocerebellar Ataxia Type 21","Spinocerebellar Ataxia Type 20","Spinocerebellar Ataxia Type 2","Spinocerebellar Ataxia Type 19\u002F22","Spinocerebellar Ataxia Type 18","Spinocerebellar Ataxia Type 17","Spinocerebellar Ataxia Type 16","Spinocerebellar Ataxia Type 15\u002F16","Spinocerebellar Ataxia Type 14","Spinocerebellar Ataxia Type 13","Spinocerebellar Ataxia Type 12","Spinocerebellar Ataxia Type 11","Spinocerebellar Ataxia Type 10","Spinocerebellar Ataxia Type 1 With Axonal Neuropathy","Spinocerebellar Ataxia Type 1","Spinocerebellar Ataxia - Unknown","Spinocerebellar Ataxia - Dysmorphism","Non Progressive Epilepsy and\u002For Ataxia With Myoclonus as a Major Feature","Spasticity-ataxia-gait Anomalies Syndrome","Spastic Ataxia With Congenital Miosis","Spastic Ataxia - Corneal Dystrophy","Spastic Ataxia","Rare Hereditary Ataxia","Rare Ataxia","Recessive Mitochondrial Ataxia Syndrome","Progressive Epilepsy and\u002For Ataxia With Myoclonus as a Major Feature","Posterior Column Ataxia - Retinitis Pigmentosa","Post-Stroke Ataxia","Post-Head Injury Ataxia","Post Vaccination Ataxia","Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract","Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus","Non-hereditary Degenerative Ataxia","Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity","Olivopontocerebellar Atrophy - Deafness","NARP Syndrome","Myoclonus - Cerebellar Ataxia - Deafness","Multiple System Atrophy, Parkinsonian Type","Multiple System Atrophy, Cerebellar Type","Multiple System Atrophy","Maternally-inherited Leigh Syndrome","Machado-Joseph Disease Type 3","Machado-Joseph Disease Type 2","Machado-Joseph Disease Type 1","Leigh Syndrome","Late-onset Ataxia With Dementia","Infection or Post Infection Ataxia","GAD Ataxia","Hereditary Episodic Ataxia","Gliadin\u002FGluten Ataxia","Friedreich Ataxia","Fragile X-associated Tremor\u002FAtaxia Syndrome","Familial Paroxysmal Ataxia","Exposure to Medications Ataxia","Episodic Ataxia With Slurred Speech","Episodic Ataxia Unknown Type","Episodic Ataxia Type 7","Episodic Ataxia Type 6","Episodic Ataxia Type 5","Episodic Ataxia Type 4","Episodic Ataxia Type 3","Episodic Ataxia Type 1","Epilepsy and\u002For Ataxia With Myoclonus as Major Feature","Early-onset Spastic Ataxia-neuropathy Syndrome","Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity","Early-onset Cerebellar Ataxia With Retained Tendon Reflexes","Early-onset Ataxia With Dementia","Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia","Dilated Cardiomyopathy With Ataxia","Cataract - Ataxia - Deafness","Cerebellar Ataxia, Cayman Type","Cerebellar Ataxia With Peripheral Neuropathy","Cerebellar Ataxia - Hypogonadism","Cerebellar Ataxia - Ectodermal Dysplasia","Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss","Brain Tumor Ataxia","Brachydactyly - Nystagmus - Cerebellar Ataxia","Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia","Autosomal Recessive Syndromic Cerebellar Ataxia","Autosomal Recessive Spastic Ataxia With Leukoencephalopathy","Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay","Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria","Autosomal Recessive Spastic Ataxia","Autosomal Recessive Metabolic Cerebellar Ataxia","Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine","Autosomal Recessive Ataxia, Beauce Type","Autosomal Recessive Ataxia Due to Ubiquinone Deficiency","Autosomal Recessive Ataxia Due to PEX10 Deficiency","Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia","Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency","Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency","Autosomal Recessive Congenital Cerebellar Ataxia","Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome","Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency","Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency","Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency","Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome","Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity","Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency","Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect","Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion","Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation","Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness","Autosomal Recessive Cerebellar Ataxia","Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly","Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation","Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy","Autosomal Dominant Spastic Ataxia Type 1","Autosomal Dominant Spastic Ataxia","Autosomal Dominant Optic Atrophy","Ataxia-telangiectasia Variant","Ataxia-telangiectasia","Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy","Autosomal Dominant Cerebellar Ataxia Type 4","Autosomal Dominant Cerebellar Ataxia Type 3","Autosomal Dominant Cerebellar Ataxia Type 2","Autosomal Dominant Cerebellar Ataxia Type 1","Autosomal Dominant Cerebellar Ataxia","Ataxia-telangiectasia-like Disorder","Ataxia With Vitamin E Deficiency","Ataxia With Dementia","Ataxia - Oculomotor Apraxia Type 1","Ataxia - Other","Ataxia - Genetic Diagnosis - Unknown","Acquired Ataxia","Adult-onset Autosomal Recessive Cerebellar Ataxia","Alcohol Related Ataxia","Multiple Endocrine Neoplasia","Multiple Endocrine Neoplasia Type II","Multiple Endocrine Neoplasia Type 1","Multiple Endocrine Neoplasia Type 2","Multiple Endocrine Neoplasia, Type IV","Multiple Endocrine Neoplasia, Type 3","Multiple Endocrine Neoplasia (MEN) Syndrome","Multiple Endocrine Neoplasia Type 2B","Multiple Endocrine Neoplasia Type 2A","Atypical Hemolytic Uremic Syndrome","Atypical HUS","Wiedemann-Steiner Syndrome","Breast Implant-Associated Anaplastic Large Cell Lymphoma","Autoimmune\u002FInflammatory Syndrome Induced by Adjuvants (ASIA)","Hemophagocytic Lymphohistiocytosis","Behcet's Disease","Alagille Syndrome","Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD)","Lowe Syndrome","Pitt Hopkins Syndrome","1p36 Deletion Syndrome","Jansen Type Metaphyseal Chondrodysplasia","Cockayne Syndrome","Chronic Recurrent Multifocal Osteomyelitis","CRMO","Malan Syndrome","Hereditary Sensory and Autonomic Neuropathy Type Ie","VCP Disease","Hypnic Jerking","Sleep Myoclonus","Mollaret Meningitis","Recurrent Viral Meningitis","CRB1","Leber Congenital Amaurosis","Retinitis Pigmentosa","Rare Retinal Disorder","KCNMA1-Channelopathy","Primary Biliary Cirrhosis","ZMYND11","Transient Global Amnesia","Glycogen Storage Disease","Alstrom Syndrome","White Sutton Syndrome","DNM1","EIEE31","Myhre Syndrome","Recurrent Respiratory Papillomatosis","Laryngeal Papillomatosis","Tracheal Papillomatosis","Refsum Disease","Nicolaides Baraitser Syndrome","Leukodystrophy","Tango2","Cauda Equina Syndrome","Rare Gastrointestinal Disorders","Achalasia-Addisonian Syndrome","Achalasia Cardia","Achalasia Icrocephaly Syndrome","Anal Fistula","Congenital Sucrase-Isomaltase Deficiency","Eosinophilic Gastroenteritis","Idiopathic Gastroparesis","Hirschsprung Disease","Rare Inflammatory Bowel Disease","Intestinal Pseudo-Obstruction","Short Bowel Syndrome","Sacral Agenesis","Sacral Agenesis Syndrome","Caudal Regression","Scheuermann Disease","SMC1A Truncated Mutations (Causing Loss of Gene Function)","Cystinosis","Juvenile Nephropathic Cystinosis","Nephropathic Cystinosis","Kennedy Disease","Spinal Bulbar Muscular Atrophy","Warburg Micro Syndrome","Mucolipidoses","Mitochondrial Diseases","Mitochondrial Aminoacyl-tRNA Synthetases","Mt-aaRS Disorders","Hypertrophic Olivary Degeneration","Non-Ketotic Hyperglycinemia","Fish Odor Syndrome","Halitosis","Isolated Congenital Asplenia","Lambert Eaton (LEMS)","Biliary Atresia","STAG1 Gene Mutation","Coffin Lowry Syndrome","Borjeson-Forssman-Lehman Syndrome","Blau Syndrome","Arginase 1 Deficiency","HSPB8 Myopathy","Beta-Mannosidosis","TBX4 Syndrome","DHDDS Gene Mutations","MAND-MBD5-Associated Neurodevelopmental Disorder","Constitutional Mismatch Repair Deficiency (CMMRD)","SPATA5 Disorder","SPATA5L1 Related Disorder","Acrodysostosis","Multi-systematic Smooth Muscle Dysfunction Syndrome","CRELD1 (Cysteine Rich With EGF Like Domains 1)","GNB1 Syndrome","Pyruvate Dehydrogenase Complex Deficiency Disease","Beta Mannosidosis","Kbg Syndrome","Labrune Syndrome","Metachromatic Leukodystrophy (MLD)","Moyamoya Disease","OPHN1 Syndrome","Oculopharyngeal Muscular Dystrophy (OPMD)","TUBB3 Mutation","WOREE (WWOX-related Epileptic Encephalopathy","SCAR12","Skraban-Deardorff Syndrome","Hereditary Myopathy With Early Respiratory Failure",[691,692,693,694,695,402,696,697,409,698,369,699,700,701,572,581,702,703,360,704,705,368,706,370,707,359,708,709,584,710,711,587,588,712,590,591,713,714,594,715,716,717,643,718,719,720,721,722,723,724,648,725,726,727,653,654,728,729,730,731,732],"Rare Diseases","Neglected Diseases","Orphan Diseases","Rare Disease Research","Registries","Ataxia","Cornelia de Lange Syndrome","Ataxia Telangiectasia","Batten Disease","Mucolipidosis IV","Klippel-Feil Syndrome","Undiagnosed","Uncommon Disease","Hypersomnia","Hyperacusis","Marinesco-Sjogren Syndrome","4p-\u002FWolf-Hirschhorn Syndrome","Narcolepsy","Wiedermann-Steiner Syndrome","Autoimmune\u002Finflammatory Syndrome Induced by Adjuvants (ASIA)","Hemophagocytic Lymphohistiocytosis (HLH)","Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia (IBMPFD)","1p36 deletion syndrome","Jansen metaphyseal chondrodysplasia","Chronic recurrent multifocal osteomyelitis (CRMO)","Malan syndrome","Hereditary Sensory and Autonomic Neuropathy","Juvenile nephropathic cystinosis","Nephropathic infantile cystinosis","Ocular cystinosis","Kennedy disease","Spinal Bulbar Muscular Atrophy (SBMA)","SMC1A Truncated Mutations (causing loss of gene function)","Leigh syndrome","Mucolipidosis","Mitochondrial aminoacyl-tRNA synthetases (Mt-aaRS Disorders)","Shine Syndrome","Intestinal Bromhidrosis Syndrome","Fish odor syndrome","Autosomal recessive extra oral halitosis","CACNA1H mutation","Dimethylglycine dehydrogenase deficiency","2025-05-22",{"date":735,"type":34},"2025-05-29",{"date":737,"type":34},"2010-07",{"date":739,"type":19},"2100-12",{"name":741,"class":90},"Sanford Health",2,{"id":744,"slug":745,"hasResults":10,"nctId":746,"briefTitle":747,"officialTitle":748,"acronym":749,"eligibilityCriteria":750,"healthyVolunteers":10,"sex":14,"minAge":70,"maxAge":4,"enrollmentInfo":751,"targetDuration":4,"studyType":131,"phases":753,"briefSummary":754,"conditions":755,"keywords":773,"overallStatus":326,"whyStopped":4,"lastUpdateSubmitDate":787,"lastUpdatePostDateStruct":788,"startDateStruct":790,"completionDateStruct":792,"leadSponsor":794,"locationsCount":40},"100582154","serological-measurement-of-montpellier-professionals-contacts-with-infectious-agents-responsible-for-animal-borne-diseases-100582154","NCT06859619","Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases","Seroprevalence of Zoonotic and Arboviral Emerging Infections in Exposed Agents from the City of Montpellier: a Transversal Study.","SEZAM","Inclusion Criteria:\n\n* Age 18 or over\n* Consultant in an infectious diseases department\n* Have given written consent to participate in the study\n* Working for the City or Metropolis of Montpellier in the Zoo, Espaces Vert or Ecolothèque departments.\n\nExclusion Criteria:\n\n* \\- Pregnant and breast-feeding women\n* Persons benefiting from legal protection measures (guardianship, curatorship, safeguard of justice)\n* Participants who are not fluent in French and who do not have a support person capable of reading French.\n* Persons unable to express their consent.\n* Persons participating in another research project with an exclusion period still in progress.\n* Persons not affiliated to a social security scheme or not benefiting from such a scheme.",{"count":752,"type":19},183,[317],"Zoonoses and arboviroses refer to a group of diseases transmitted from animals to humans, either directly or indirectly (via mosquitoes, ticks or contact with contaminated environments). Most of these diseases are found in certain tropical zones, but global warming and increased international trade are modifying their geographical distribution, with a gradual trend towards temperate regions. A number of these pathogens have already been detected in Occitania, including dengue fever, West Nile, leishmaniasis and Q fever. Given the region's high mosquito population and favorable climatic conditions, other zoonoses have a strong potential to appear in the region, or may already be circulating at a low level. The study focuses on 18 pathogens selected for their potential to emerge and establish themselves in the Occitanie region: Leishmaniasis, Leptospirosis, Brucellosis, Q fever, Rickettsiosis, Tularemia, Psittacosis, Lyme disease, Tick-borne encephalitis, Hantavirus, Hepatitis E virus, Dengue virus, Zika virus, Chikungunya virus, West-Nile virus, Usutu virus, Toscana virus, Crimean-Congo haemorrhagic fever virus.\n\nThe aim of the study is to find out whether patients have antibodies against these infectious agents, which would indicate that they have been exposed to them in the past, even in the absence of symptoms.\n\nDescribing the circulation of these pathogens will enable to implement appropriate public health measures to avoid the risk of epidemics (mosquito control, informing professionals, etc.), as well as to assess the risk incurred in the workplace and have this risk recognized by the healthcare system.",[756,757,758,759,760,761,762,23,763,764,765,766,767,768,769,770,771,772],"Leishmaniasis","Leptospirosis","Brucellosis","Q Fever","Rickettsiosis","Tularemia","Psittacosis","Tick-borne Encephalitis","Hantaviral Infection Nos","Hepatitis E","Dengue Virus","Zika Virus","Chikungunya Virus Infection","West Nile Virus","Usutu Virus","Toscana Virus","Crimean-Congo Haemorrhagic Fever Virus",[774,757,758,775,776,253,777,778,779,780,781,782,783,784,761,762,785,786],"Leishmaniasis,","Zika virus","Q fever, Rickettsiosis","Tick-borne encephaliti","Hantavirus","Hepatitis E virus","Dengue virus","Chikungunya virus","West-Nile virus","Usutu virus","Toscana virus","Crimean-Congo haemorrhagic fever virus","epidemiology","2025-02-27",{"date":789,"type":34},"2025-03-05",{"date":791,"type":19},"2025-03-03",{"date":793,"type":19},"2025-10-03",{"name":795,"class":90},"University Hospital, Montpellier",{"id":797,"slug":798,"hasResults":10,"nctId":799,"briefTitle":800,"officialTitle":801,"acronym":802,"eligibilityCriteria":803,"healthyVolunteers":10,"sex":14,"minAge":70,"maxAge":4,"enrollmentInfo":804,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":806,"conditions":807,"keywords":819,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":824,"lastUpdatePostDateStruct":825,"startDateStruct":827,"completionDateStruct":829,"leadSponsor":831,"locationsCount":152},"100317883","central-nervous-system-infections-in-denmark-100317883","NCT03418441","Central Nervous System Infections in Denmark","Danish Study Group of Infections of the Brain: A Nationwide Prospective Observational Cohort Study of All Central Nervous System Infections in Adults at Departments of Infectious Diseases in Denmark","DASGIB","Definitions of central nervous system infections:\n\nFor all cases with unproven aetiologies no alternative diagnosis than CNS infection is thought more likely after completed multidisciplinary diagnostic work-up.\n\nViral meningitis inclusion criteria\n\n\\- All patients have to have a clinical presentation consistent with non-bacterial meningitis (e.g. headache, neck stiffness, photo- or phonophobia, fever)\n\nand\n\nCerebrospinal fluid leukocytes\\>10 cells\u002Fml\n\nPatients with viral meningitis with undetermined pathogen have to have:\n\n* CSF leukocytes\\> 10\u002FmL and no other more probable diagnosis assessed by the local investigator.\n\nIn case of doubt, patients are discussed with the DASGIB secretary and chair or at meetings.\n\nBacterial meningitis inclusion criteria - All patients have to have a clinical presentation consistent with bacterial meningitis (e.g. headache, neck stiffness, fever, altered mental status)\n\nand\n\nProven bacterial aetiology (CSF or blood culture\u002FDNA based technology or antigen tests)\n\nPatients with bacterial meningitis in whom the bacteria cannot not be cultured or identified by DNA-based technologies have to have:\n\n\\- CSF leukocytes\\> 10\u002FmL and no other more probable diagnosis assessed by the local investigator.\n\nIn case of doubt, patients are discussed with the DASGIB secretary and chair or at meetings.\n\nEncephalitis inclusion criteria - All patients have to have a clinical presentation consistent with encephalitis (e.g. headache, fever, focal neurological deficit, altered mental status \\>24 hours) as defined by the International Encephalitis Consortium (Venkatesan A et al., Clin Infect Dis 2013; doi:10.1093\u002Fcid\u002Fcit458.).\n\nEncephalitis exclusion criteria\n\n\\- We exclude cases of proven or suspected autoimmune encephalitis.\n\nPrimary brain abscess inclusion criteria\n\n\\- All patient have a clinical presentation consistent with brain abscess (e.g. headache, focal neurological deficit, mass lesion on cranial imaging)\n\nand\n\n\\- Proven microbiological aetiology by culture\u002FDNA-based technology from pus from brain abscess or blood or CSF\n\nor\n\n\\- Aspiration of pus from the brain abscess\n\nor\n\n\\- Response to antimicrobial treatment\n\nor\n\n\\- Tumour ruled out\n\nor\n\n\\- Tumour thought less probable than abscess on MRI using diffusion weighted imaging (DWI) and apparent diffusion coefficient (ADC) sequences.\n\nLyme neuroborreliosis inclusion criteria\n\n\\- A clinical presentation consistent with neuroborreliosis (e.g. radiculopathy)\n\nand\n\n\\- CSF pleocytosis\\>10 leukocytes\u002FmL\n\nand\n\n\\- Positive intrathecal B.burgdorferi antibody production index.\n\nNeurosyphilis inclusion criteria - A clinical presentation consistent with neurosyphilis (e.g. 'encephalitis-like symptoms', dementia, ocular or otogenic syphilis)\n\nand either\n\n\\- Positive syphilis serology in serum combined with CSF leukocytes\\>10\u002FmL\n\nor\n\n\\- CSF syphilis antibodies.",{"count":805,"type":19},1900,"The Danish Study Group of Infections of the Brain is a collaboration between all departments of infectious diseases in Denmark. The investigators aim to monitor epidemiological trends in central nervous system (CNS) infections by a prospective registration of clinical characteristics and outcome of all adult (\\>17 years of age) patients with community-acquired CNS infections diagnosed and\u002For treated at departments of infectious diseases in Denmark since 1st of January 2015.",[808,809,810,811,812,813,814,815,23,816,817,818],"Central Nervous System Infections","Bacterial Meningitis","Viral Meningitis","Aseptic Meningitis","Encephalitis","Brain Abscess","Neuroborreliosis","Neurosyphilis","Tertiary Syphilis","Cerebral Abscess","Meningitis",[820,821,808,818,812,822,253,814,815,823],"Nationwide prospective observational cohort study","Epidemiology","Brain abscess","Tertiary syphilis","2024-05-15",{"date":826,"type":34},"2024-05-16",{"date":828,"type":34},"2015-01-01",{"date":830,"type":19},"2030-01-01",{"name":832,"class":90},"Aalborg University Hospital"]